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1. ABSTRACT
The intestinal mucus gel layer represents a stumbling block for drug adsorption. This study is
aimed to formulate a nanoparticulate system able to overcome this barrier by cleaving locally
the glycoprotein substructures of the mucus. Mucolytic enzymes such as papain (PAP) and
bromelain  (BRO)  were  covalently  conjugated  to  poly(acrylic  acid)  (PAA).  Nanoparticles
(NPs) were then formulated via ionic gelation method and characterized by particle size, zeta
potential, enzyme content and enzymatic activity. The NPs permeation quantified by rotating
tube studies was correlated with changes in the mucus gel layer structure determined by
pulsed-gradient-spin-echo NMR (PGSE-NMR), small-angle neutron scattering (SANS) and
spin-echo SANS (SESANS). PAP and BRO functionalized NPs had an average size in the
range of 250 and 285 nm and a zeta potential that ranged between -6 and -5 mV. The enzyme
content was 242 µg enzyme/mg for PAP modified NPs and 253 µg enzyme/mg for BRO
modified NPs. The maintained enzymatic activity was 43% for PAP decorated NPs and 76%
for BRO decorated NPs. The rotating tube technique revealed a better performance of BRO
decorated NPs compared to PAA decorated NPs, with a 4.8 fold higher concentration of NPs
in the inner slice of mucus. Addition of 0.5wt% of enzyme functionalized NPs to 5wt%
intestinal mucin led to c.a. 2 fold increase in the mobility of the mucin as measured by PGSE-
NMR indicative of a significant break-up of the structure of the mucin. SANS and SESANS
measurements further revealed a change in structure of the intestinal mucus induced by the
incorporation of the functionalized NPs mostly occurring at a lengthscale longer than 0.5 μm.
Accordingly, BRO decorated NPs show higher potential then PAP functionalized NPs as
mucus permeating drug delivery systems.
Keywords: mucus permeating nanoparticles, papain, bromelain, oral drug delivery
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2. INTRODUCTION
Among all the administration routes the oral one is the most favorable, however the low oral
bioavailability of numerous drugs is a major issue and strategies able to improve drug
solubility and adsorption are needed. One of the main causes of low drug oral bioavailability
is the presence of a barrier that covers all the surface of the GI tract, namely the mucus barrier.
This continuous gel layer is a complex matrix formed mainly by mucin, a polypeptide with
highly glycosylated negatively charged regions, hydrophobic regions and cysteine rich
regions interconnected via disulfide bonds. Mucus is a semipermeable barrier that guaranties
the  exchange  of  nutrients,  gases  and  water  and  prevents  the  permeation  of  many  pathogens
and foreign particles [1]. In recent years many attempts have been undertaken to formulate
drug delivery systems (DDSs) able to overcome this barrier. A strategy that showed potential
was a nanoparticulate system bearing mucolytic agents able to cleave the mucus substructure
in front of them and therefore to cross this barrier. An in vivo study showed a prolonged
residence time, compared to not functionalized NPs, in the small intestine of rats [2]. As this
preliminary study showed great potential, it is worth to continue working in this direction to
further improve such systems and the analytical methods needed behind. Accordingly, it was
the aim of this study to compare the features of the papain (PAP) conjugated nanoparticles
(NPs) with a new carrier bearing bromelain (BRO). The chosen enzymes are stable in
simulated intestinal fluid as demonstrated by in vitro studies and their maintained
mucolytic activity and ability to permeate through the intestine was demonstrated by
several in vivo studies [3-6]. However the enzymes are digested in gastric environment
and therefore enteric coat is necessary for in vivo application. Both enzymes are known to
decrease the intestinal mucus viscosity [7] but, to our knowledge, a systematic comparison
between PAP and BRO modified NPs has not been performed yet. BRO was selected for the
formulation of functionalized NPs in order to improve the tolerability of the carrier. In fact,
beside the known occupational allergy caused by both enzymes (means a long term work
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related exposure) [8-11], just one case of allergic reaction associated with BRO ingestion
could be found in the literature [12], while several cases of non-occupational allergic
sensitization  were  reported  for  PAP  [13,  14].  Moreover,  a  series  of  clinical  trials  were
performed in the past decade, last one published in 2013, illustrating the good tolerability to
BRO ingestion by patients [15-18]. Poly(acrylic) acid was chosen as polymeric backbone for
this DDS as it shows weak mucoadhesive properties [19] and bears carboxylic groups to
which enzymes can be conjugated via carbodiimide chemistry [20]. The reaction can take
place at the amino terminal group of both enzymes and at lysine residues, which are 10 for
PAP and 15 for BRO [21, 22]. To further investigate and gain a deeper understanding of the
enhancing permeation properties of this new DDS, the results obtained with previously
established techniques were correlated with the results obtained exploiting innovative
techniques (such as pulsed-gradient spin-echo NMR, small-angle neutron scattering and spin-
echo small angle neutron scattering) yielding information on the effect of these NPs on the
structure of mucus at small lengthcales.
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3. MATERIALS AND METHODS
3.1. Materials
Poly(acrylic) acid (PAA, solution 35wt% in H2O, average molecular weight 100 kDa),
papain from carica papaia 3.6 U/mg (EC 3.4.22.2), bromelain from pineapple steam 3.4 U/mg
(EC 3.4.22.32), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC), N-
hydroxysuccinimde (NHS), ethylenediaminetetraacetic acid (EDTA), casein, L-cysteine,
trehalose, trichloroacetic acid (TCA), resazurin and  all other salts and solvents at analytical
grade were purchased from Sigma – Aldrich (Vienna, Austria). Lumogen red was purchased
from  Kremer  pigmente  GmbH  &  Co.  KG  (Aichstetten,  Germany).  Bicinchoninic  acid  kit
(BCA) was purchased from Thermo Scientific (Vienna, Austria). Minimum essential medium
(MEM) was purchased from Biochrome AG (Berlin, Germany). Intestinal mucin (Imucin) and
intestinal mucus (Imucus) were obtained from Jeff Pearson (Newcastle University, Institute
for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom).
3.2. Polymer synthesis
3.26 g of PAA solution, corresponding to 1 g of polymer (MW 100 kDa, 0.01 mmol), was
diluted in 1 L of water, pH adjusted to 6, to obtain a 0.1wt% solution. 5 g of EDAC (191.7 Da,
26.08 mmol) and 3 g of NHS (115.09 Da, 26.07 mmol) were dissolved in 100 mL of water
and added to the polymer solution. The reaction mixture was incubated for 1 h under vigorous
stirring. Then, 1 g of PAP (theoretical molecular weight 23.4 kDa, 0.043 mmol [23]) or 1.42 g
of BRO (approximate  molecular weight 33 kDa, 0.043 mmol [24]) was dissolved in 500 mL
of water and slowly added to the reaction mixture and stirred for 24 h at 10°C. The obtained
enzyme-polymer conjugate was dialyzed against demineralized water for 3 days at 10°C. The
solutions were then lyophilized yielding a white powder referred as PAA-PAP and PAA-BRO,
respectively [2].
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3.3. Nanoparticles formulation
100 mg of PAA or enzyme-polymer conjugate were dissolved in 10 mL water to obtain a
1wt% solution and the pH was adjusted to 8. This mixture was slowly added to 7.5 mL of
Lumogen aceton solution 0.07 mg/mL. After 10 min equilibration 1 mL of CaCl2 5 mg/mL
dissolved in water was added drop by drop and stirred for 30 min. The suspension was then
centrifuged at 5500 rpm (4966 x g) for 25 min (MiniSpin centrifuge, Eppendorf), the
supernatant discarded and the pellet washed with 50vol% aceton/water mixture for three times.
Finally the washed pellet was resuspended in 1wt% trehalose/water solution by means of
probe sonication for 10 sec and then lyophilized. The obtained products were referred to PAA
NPs when PAA was used for the formulation, PAA-PAP NPs when PAA-PAP was used for
the formulation and PAA-BRO NPs when PAA-BRO was used for the formulation.
3.4. Nanoparticles characterization
Nanoparticle particle size and charge characterization was carried out by using a
NICOMPTM 380 ZLS PSS (Particle Sizing Systems, CA, USA). Particle size was recorded at
a scattering angle of 90° for 10 min at room temperature. Zeta potential was recorded under
electric field strength of 5 V/cm for 3 minutes at room temperature.
3.5. Enzyme quantification
The amount of enzyme conjugated to polymers and nanoparticles was determined by micro
BCA protein assay, following the provider´s instruction. The samples were dissolved in 0.1 M
NaOH solution containing 1.5wt% of sodium dodecyl sulfate to obtain a concentration of 0.1
mg/mL. The samples were incubated at 25°C in a thermomixer (Thermomixer Conform;
Eppendorf, Hamburg, Germany) under constant shaking, 1000 rpm for 2 h. Thereafter, 150
µL of sample were mixed with 150 µL of working reagent in a 96 well plate and incubated for
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further 2 h at 37°C. Finally the absorbance was detected at 562 nm by using a microplate
reader (TECAN Infinite M200, Austria GmbH). The amount of enzyme was extrapolated by
fitting the data to a calibration curve obtained via analyzing solution with different
concentration of PAP or BRO. The enzyme content of polymers and NPs was reported on a
weighted  base  as  the  ratio  between  the  amount  of  conjugated  enzyme  and  the  amount  of
polymers  or  NPs.  The  conjugation  efficacy  onto  the  polymers  was  calculated  as  weight
percent of the amount of conjugated enzyme relative to the initial amount of enzyme used.
3.6. Enzymatic activity assay
The remaining enzymatic activity of conjugated enzyme was detected via casein assay [25].
The polymers were dissolved and the particles were dispersed at a concentration between
0.5 and 1 mg/mL in PBS 50 mM pH 8 containing 2 mM EDTA and 5 mM L-cysteine. The
solutions were then diluted with 2 mL of PBS 10 mM pH 8 and further with 1 mL of 2wt%
casein solution. The reaction mixtures were incubated for 30 min at 37°C in a thermomixer
under constant shaking, 750 rpm. After incubation 120 µL of 100wt% TCA solution was
added in order to stop the reaction. The samples were then centrifuged for 10 min at 13400
rpm (12100 x g) and the absorbance of the supernatant detected at 280 nm. The assay was
performed in parallel with solutions presenting the same enzyme concentration of each
sample. The remaining enzymatic activity of the enzyme-conjugated samples was calculated
as percentage comparing the absorbance of the samples and the pure enzyme solutions.
3.7. Cytotoxicity assay
The cytotoxicity of polymers and NPs was tested in Caco-2 cells by resazurin assay. Caco-2
cell were seeded on 96-well plates at a concentration of 104 cells/well and cultivated for 24 h
at 37°C and 5% CO2. Thereafter, the medium was discarded and 100 µL of polymers and NPs
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dissolved/dispersed in   MEM not supplemented with fetal bovine serum at different
concentration (0.1-2 mg/mL) was added. After 4 h incubation to each well 100 µL of
resazurin solution 88 µM dissolved in not supplemented MEM was added and incubated for 2
h. Finally the fluorescence intensity (λex 540 nm, λem 590 nm) was determined. As control,
100 µL of polymers and NPs dissolved/suspended in not supplemented MEM at different
concentrations (0.1-2 mg/mL) were incubated without cells for 4 h. Theses samples were
treated with resazurin as described above and the fluorescence intensity was measured.
The fluorescence intensity of the samples incubated without cells was subtracted to the
fluorescence intensity of the samples incubated with cells at the same concentration. The
data were reported as percentage of viable cells considering the negative control  (cells
incubated with MEM) as 100% viability. As positive  control  Triton X 1wt% dissolved in
MEM was used.
3.8. Intestinal mucus collection
Pig small intestines were obtained from a local abattoir immediately after slaughter and
transported on ice to the laboratory.  Sections of the intestines that did not visibly contain
chyme were cut into ~15 cm lengths and mucus was removed.  To remove the mucus gentle
pressure was applied to one end of the length with the fingers and continuously applied
unidirectionally to the opposite end. If the mucus contains debris the mucus was cleaned as
follows. The mucus was gently stirred (<100 rpm) for 1 h at 4°C in sodium chloride (0.1 M)
at a ratio of 1 g mucus to 5 ml sodium chloride. The mixture was then centrifuged at 9000
rpm (10,400 x g) at 10°C for 2 h.  The supernatant was discarded as well as the granular
material at the bottom.  The clean portion of the mucus was added to half the volume of
sodium chloride (0.1 M) used for first washing.  This was stirred (<100 rpm) for 1 h at 4°C
and then centrifuge at 9000 rpm at 10°C for 2 h.  The supernatant was discarded and only the
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clean portion of the mucus was collected.  Cleaned mucus (Imucus) was stored in aliquots at -
20°C until use.
3.9. Mucin purification from porcine mucus
Mucus gel was collected as described above but added to a cocktail of enzyme inhibitors in
phosphate buffer, pH 6.8 [26].  The mucus was not cleaned prior to mucin purification.  The
mucin (Imucin) was purified following the protocol described by Taylor et al., with the
addition of a second caesium chloride gradient to further remove cellular debris from the
glycoprotein component of mucus.  All freeze dried sample were stored at -20oC until used.
3.10. Permeation study
The permeation ability of the prepared NPs was investigated by the rotating tube technique
[27].  Plastic tube with a length of 30 mm and a diameter of 4 mm were filled in with Imucus
exploiting  a  syringe  without  needle.  One  end  of  the  tube  was  closed  with  parafilm,  on  the
other end 100 µL of NPs, (previously resuspended by means of probe sonication for 10 sec in
simulated intestinal fluid without pancreatin (SIF) (1 mg/mL)), was added. For each sample
six replicates were prepared. After preparation the tubes were incubated at 37°C for 4 h under
a constant horizontal stirring (≈50 rpm). A scheme representing the system is illustrated in
Figure 1. Thereafter, the tubes were frozen at -80°C and cut into slices of 2 mm length. Each
slice  was  incubated  with  150  µL DMSO,  left  overnight  at  room temperature  protected  from
light and then ultrasonicated for 1 h. After centrifugation for 2 min at 13400 rpm (12100 x g)
the fluorescence intensity of the supernatant (λex 578 nm, λem 613 nm) was determined in
order  to  assess  the  depth  of  particles  diffusion  into  the  mucus.  As  control,  the  test  was  run
each time with a tube filled with Imucus without NPs. The obtained fluorescence intensity of
the Imucus was subtracted to the fluorescence intensity of the samples.
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Figure 1. Schematic representation of the rotating tube technique.
3.11.Pulsed-gradient spin-echo NMR assessment of mucin mobility
Pulsed-gradient spin-echo NMR (PGSE-NMR) measurements were performed on a Bruker
DMX400 NMR spectrometer operating at 400 MHz (1H) using a stimulated echo sequence
[28]. All the experiments were run at 37ºC using the standard heating/cooling system of the
spectrometer to an accuracy of ±0.3ºC. All solutions were prepared from stock solutions and
made up in SIF with the exception that D2O was used in place of H2O. The NPs formulations
(containing  calcium  chloride  and  trehalose)  were  dispersed  in  SIF  to  a  concentration  of
0.5wt% NPs (equivalent to 7.5wt% of formulation). Imucin was then dissolved in the
respective samples (final concentration 5wt%) and left to equilibrate for 24h. 0.6 mL were
transferred to 5 mm o.d. NMR tubes (Willmad NMR tubes form Sigma-Aldrich).
Generally, the self-diffusion coefficient, D, is deduced by fitting the attenuation (decay) of the
integral for a chosen peak to eqn.1,
A(δ,G,Δ)=A0exp(-kD) (1)
where A is the signal intensity and k=-γ2G2 δ2(Δ-δ/3),  where γ is  the magnetogyric ration, ∆
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the  diffusion  time,  δ the  gradient  pulse  length,  and  G  is  the  gradient  field  strength.  The
gradient pulses are ramped to their desired value over a ramp time, σ, typically 250 µs.
For complex spectra such as those encountered here, the diffusion data are better analysed by
fitting to this equation the entire bandshape using “CORE”, a program devised to resolve the
various components present in such data [29]. CORE permits the selection of significant
regions of peak intensity within the spectra as well as the ability to “mask out” any unwanted
regions , such as peak e.g. H2O arising from background components of no interest.
CORE  evaluates  the  experimental  data  in  two  dimensions  by  a  global  least  squares  fit,
yielding  estimations  of  the  diffusion  coefficients  for  each  component  in  the  sample.  The
output data include the fitted parameters of the optimized model, the global fit and the global
difference map.
3.12.SANS and SESANS
Small-angle neutron scattering (SANS) is a powerful technique for determining
microstructure in the dimension range of 1 to 400nm. SANS experiments were performed on
the  fixed-geometry,  time-of  flight  SANS2D  diffractometer  at  the  ISIS  Spallation  Neutron
Source, Rutherford Appleton Laboratory ( Didcot, United Kingdom). A Q = (4π/λ) sin(θ/2)
range between 0.004 and 0.3 Å-1 is obtained by using neutron wavelengths (λ) spanning 1.8 to
16.5 Å with a fixed sample-detector distance of 4.0 m. The samples were contained in
demountable 1 mm path length, UV-spectrophotometer grade, quartz cuvettes (Starna) and
mounted  in  aluminum holders  on  top  of  an  enclosed,  computer-controlled,  sample  chamber.
All experiments were conducted at 37 °C. NPs and free enzymes were incubated with Imucus
for 3 hours prior to measurement. The concentration of free enzyme in the samples was
chosen to be equivalent to the amount of enzyme present in the samples containing enzyme
conjugated NPs. All scattering data were (a) normalized for the sample transmission, (b)
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background corrected using a quartz cell filled with D2O, and (c) corrected for the linearity
and efficiency of the detector response using the instrument specific software package.
Spin-echo small angle neutron scattering (SESANS) is a newer technique allowing the
determination of material structure in the length range between 300 and 6000 nm.  In this
experiment, the neutron beam was split and the two halves polarized. Since polarized and
non-polarized neutrons probe structure differently, the ratio of their intensities becomes a
measure of any structure present, over a distance scale defined by the evolution period used in
the experiment. The latter allows us to extend the lengthscale probed by several orders of
magnitude. In both experiments, the effect of free enzymes or enzyme conjugated NPs on the
sample scattering was followed for a period of c.a. 5h.
3.13.Statistical data analysis
All experiments were performed with at least three replicates and the data are reported as
mean ± standard deviation (SD). Statistical data analyses were performed by Student´s t-test,
calculated with GraphPad Prism version 5.01. The utilized minimum level of significance was
p < 0.05.
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4. RESULTS
4.1. Polymer synthesis
PAP and BRO were successfully conjugated to the PAA backbone. The reaction was repeated
four  times  for  each  enzyme showing reproducibility,  the  results  are  reported  as  mean of  the
different experiments. The synthesis procedure resulted to be efficient with a product recovery
of about 59-73% depending on the enzyme used. For the reaction an equal amount of PAP
and BRO expressed in mmol, calculated making use  of the enzyme theoretical molecular
weight was exploited in order to obtain the most similar degree of enzyme conjugation to the
PAA backbone. The conjugation efficacy, calculated as described above, was slightly higher
for PAA-BRO than for PAA-PAP. This resulted in greater enzyme content on a weighted base
for PAA-BRO compared to PAA-PAP as reported in Table 1. The enzyme conjugation onto
the polymeric scaffold provoked a loss of enzyme activity, when compared to the native
enzyme activity, of about 58% and 37% for PAP and BRO, respectively. In order to detect
the maximum enzymatic activity the assay was performed in presence of cysteine, a
common activator of cysteine proteases, such as papain and bromelain, exhibiting a
nucleophilic cysteine thiol in their catalytic triad.
Table 1. Characteristics of the enzyme-polymer conjugates.  Results  are  the  mean of  four
different synthesis of each polymer (± standard deviation).
Polymer Yield % Enzyme
content
µg/mg
Enzyme
content
nmol/mg
Enzyme
conjugation
efficacy %
Enzymatic
activity %
PAA-PAP 72.59 ± 23.60 230.09 ±
71.32
9.83 ± 3.05 30.01 ± 8.39 42.21 ± 19.54
PAA-BRO 59.16 ± 15.19 338.40 ±
78.48
10.24 ± 2.38 44.67 ± 14.43 63.31 ± 20.72
  
14
4.2. Nanoparticles formulation and characterization
NPs were formulated by ionic gelation method exploiting Ca2+ as counter ion. The NPs
formation was optimal at pH 8 as the polymers were sufficiently charged to interact with Ca2+
ions. The characteristics of the NPs resuspended in SIF after lyophilization as mean of four
different preparation per formulation are reported in Table  2. Enzyme-conjugated and
unmodified NPs were monodispersed with a diameter included between 235 nm and 285 nm.
The zeta potential resulted to be negative for all three formulations with slightly higher values
for the enzyme-modified NPs. This decrease in negative charges for the modified NPs could
confirm the formation of the covalent bound between the mucolytic agent and the carboxylic
group of PAA. The NPs were stable during centrifugation and lyophilization with trivial
variation  in  size  and  poydispersity  index  (data  not  showed).  The  enzyme  content  for  PAA-
PAP NPs and PAA-BRO NPs,  assessed  after  treatment  with  1.5wt%  sodium  dodecyl
sulfate leading to particles disaggregation (confirmed by DLS measurement), was
comparable for both products. On the contrary, BRO maintained an higher enzymatic activity
compared to the native enzyme in respect to PAP. The enzyme activity loss after NPs
formation was equal to 57% and 24% for PAA-PAP NPs and PAA-BRO NPs, respectively.
Table 2. Characteristics of the tested nanoparticles. Results are the mean of four different
formulations per each sample (± standard deviation).
NPs Particle size
(nm)
Polydispersity
index
Zeta
potential
(mV)
Enzyme
content
µg/mg
Enzyme
content
nmol/mg
Enzymatic
activity %
PAA NP 234.87 ±
50.39
0.11 -9.37 ± 2.00
PAA-PAP
NP
257.07 ±
109.38
0.19 -6.35 ± 3.63 242.02 ±
120.72
10.34 ±
5.16
43.14 ±
5.39
PAA-BRO 285.27 ± 0.20 -5.09 ± 0.49 253.31 ± 7.68 ± 76.04 ±
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NP 119.61 120.55 3.65 8.08
4.3. Cytotoxicity test
The  cytotoxycity  of  polymers  and  NPs  was  tested in vitro via  resazurin  assay.  Both  PAP
modified polymer and NPs resulted to be not toxic at all the concentrations tested. PAA-BRO
was found to be more toxic compared with PAA-PAP with a cell availability of about 50% at
all concentrations tested. On the contrary, BRO functionalized NPs were not significantly
toxic at concentration lower then 0.2 mg/mL (Figure 2).
Figure  2. Cytotoxicity of PAA-PAP (white bars), PAA-PAP NPs (dotted bars), PAA-BRO
(gray bars) and PAA-BRO NPs (striped bars) determined by resazurin assay after 4 h
incubation with Caco-2 cells.  Values are the means of three experiments (± standard
deviation).
4.4. Permeation study
The permeation study assessed the depth of NPs diffusion into porcine Imucus. Both PAA-
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PAP NPs and PAA-BRO NPs could permeate till the last Imucus segments while unmodified
PAA NPs were detected only in the first few Imucus segments. These results confirm that
particulate systems formulated with mucolytic enzyme conjugated polymers exhibit enhanced
permeation compared to non-decorated DDS. Moreover, these results indicate higher
permeation  ability  for  PAA-BRO NPs  compared  with  PAA-PAP NPs.  In  fact,  at  segment  3
the concentration of PAA-BRO NPs is 4.8 fold higher in respect to PAA-PAP NPs, meaning
that  a  higher  percentage  of  BRO  decorated  NPs  possess  the  ability  to  permeate  the  Imucus
barrier in comparison to the PAP-modified system (Figure  3).
Figure  3. Permeation studies of PAA NPs (black bars), PAA-PAP NPs (dotted bars) and
PAA-BRO NPs (gray bars), in porcine Imucus. Particles suspended in SIF pH 6.8 were
incubated for 4 h at 37°C. * p<0.05 vs PAA NPs, ** p<0.05 vs PAA-PAP NPs. Values are the
means of six experiments (± standard deviation).
4.5. PGSE-NMR
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Diffusion  measurements  of  PAA  NPs  and  enzyme  conjugated  NPs  incubated  in  simple
SIF or 5wt% Imucin in SIF were undertaken by PGSE-NMR, Figure 4. a-c. The
intensity of a given peak or series of peaks in the NMR spectrum decreases as a function
of increasing field gradient strength, in essence, quantifying the displacement the mucin
molecules during a fixed time. A rapidly decaying signal corresponds to a high mobility,
and a large diffusion coefficient.
Analysis of these diffusion data for simple NPs incubated in SIF revealed that the single
in the NMR spectrum arose entirely from the stabilizer (trehalose), Figure 4.a, as
anticipated,  since  the  signal  from the  NPs  is  too  weak to  be  visible.  The  analysis  hence
focused on changes observed in the diffusion rate of the mucin in the sample, rather
than  the  particle  itself,  a  rather  appealing  contrast  to  the  particle  diffusion  in  the
rotating tube experiment. Since, trehalose is also visible in the samples incubated with
Imucin, the diffusion coefficient attributed to trehalose was then ignored and only the
signal corresponding to the mucin was considered in the analysis. These diffusion
coefficients, as well as the diffusion coefficient ratio of the diffusion of Imucin alone and
the diffusion coefficient of the Imucin when incubated with NPs are reported in Table 3.
As may be seen, the diffusion coefficient of mucin is only weakly affected by the blank PAA
NPs confirming the absence of any significant attractive interactions between the PAA and
the mucin gel. On the other hand, enzyme conjugated NPs lead to a 2 fold increase in Imucin
diffusivity, indicating that the Imucin is more mobile due to the destruction of its structure.
Precisely, Imucin showed a greater diffusion coefficient ration when incubated with PAA-
BRO NPs (2.4) compared to PAA-PAP NPs (1.9). It is also worth noting that the sample
containing Imucin alone fitted best to two diffusion coefficients (Dfast=4.2*10-11m2.s-1 (75%
of signal), Dslow=1.3*10-13m2.s-1 (25% of signal) highlighting the heterogeneous nature of the
sample, i.e. gelled and non-gelled components. The sample containing Imucin incubated with
blank PAA NPs also fitted best to 2 diffusion coefficients (similar values to I mucin only); the
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samples incubated with enzyme conjugated NPs, however, fitted best to 1 diffusion
coefficient  indicating  that  the  stiff  gel  part  of  the  Imucin  no  longer  exists,  an  insight  that
would not be accessible by any other technique.
Figure 4a: PAA-BRO NPs in SIF Figure 4b: PAA-BRO NPs with
Imucin in SIF
Figure 4c: Imucin in SIF
Figure   4. Raw  PGSE-NMR  data  from  which  the  diffusion  coefficient  of  the  Imucin  and
related components were extracted.
Table 3.  Absolute and relative diffusion coefficients for Imucin in the presence of the three
nanoparticles; PAA NPs, PAA-PAP NPs and PAA-BRO NPs.
Diff coef /1011 m2.s-1 Diffusion coefficient ratio
(Diff sample/Diffmucin)
Imucin only 3.2 1
With PAA NPs 2.8 0.9
With PAA-PAP NPs 6.0 1.9
With PAA-BRO NPs 7.6 2.4
4.6. SANS and SESANS
Two rather different neutron experiments were employed to characterise the structure of
mucus over quite wide ranges of length-scale to map the molecular level interactions to the
macroscopic scale.  The effect on the mucus scattering of the presence of (i) enzyme alone,
and (ii) enzyme conjugated particles has been explored. Figures 5 and 6 show the SANS
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from (i) Imucus alone, (ii) Imucus incubated with 1wt% enzyme conjugated NPs and
(iii) Imucus incubated with an equivalent amount of free enzyme. Figure 5 refers to the
PAP  case,  figure  6  the  BRO.  The  scattering  from  Imucus  exhibits  a  strong  Q-2.6
dependency characteristic of the fractal-like structure of a dense gel network [30, 31].
The samples incubated with particles or enzymes show essentially identical scattering, as
the mucus is the main component. No scattering arising from the NPs or the enzymes is
expected. The lack of change in the Imucus scattering indicates that the structure of
mucus is not significantly affected by either free enzyme or enzyme conjugated NPs, at
least on the lengthscale probed here, i.e. 1-400 nm. Subtle changes were observed in the
scattering - slight inflection at Q=0.1Å-1 – in those samples containing PAA-PAP and
PAA-BRO NPs indicative of a structure with a dimension/spacing of around 6.5 nm.
Figure  5.  Scattering intensity I(Q) as a function of wavevector Q for Imucus and the same in
the presence of 1wt% PAA-PAP NPs and the equivalent amount of free enzyme.
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Figure  6. Scattering intensity I(Q) as a function of wavevector Q for Imucus and the same in
the presence of 1wt% PAA-BRO NPs and the equivalent amount of free enzyme.
Particle-induced changes in the mucus gel structure were observed on the larger length-
scales – i.e. the SESANS data rather than the SANS data as shown in Figures 7 and 8. A
similar maximum correlation length of c.a.  3.50μm (that  can be  read off  the  Spin  echo
length axis for each curve where the depolarisation ࢒࢔	(ࡼ࢙ࢇ࢓࢖࢒ࢋ
ࡼ૙∗ࣅ
)  does not decrease
anymore) is observed in the mucus samples before and after incubation with NPs
indicating that this the gel is not affected up to this lengthscale. The larger depolarisation
(decrease in ݈݊	(௉ೞೌ೘೛೗೐
௉బ∗ఒ
)) for the mucus samples incubated with NPs indicates that a structural
change has occurred and the samples appear more compact which may be imputed to a local
breaking down of the gel network.
These two scattering techniques taken together imply that the local structure of the gel defined
by the  component  polymers  is  retained  (and  hence  for  example  the  stiffness  of  the  gel),  but
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that the larger lengthscale changes are manifest via a perturbation in the cross-link density
Figure  7. Polarization as a function of spin echo for Imucus and the same in the presence of
1wt% PAA-PAP NPs incubated for 0h45m and 4h30min. The arrow indicates the largest
length scale characteristic for the density distribution.
Figure  8. Polarization as a function of spin echo for Imucus and the same in the presence of
1wt% PAA-BRO NPs incubated for 0h10m and 4h30min. The arrow indicates the largest
Spin echo length / nm
0 1000 2000 3000 4000 5000 6000
ln
(P
sa
m
pl
e/(
P
0*
l)
)
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0 Imucus
Imucus with 1wt% PAA-PAP NPs - 0h45min
Imucus with1wt% PAA-PAP NPs - 4h30min
Spin echo length / nm
0 1000 2000 3000 4000 5000 6000
ln
(P
sa
m
pl
e/(
P
0*
l)
)
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0 Imucus
Imucus with 1wt% PAA-BRO NPs - 0h10m
Imucus with 1wt% PAA-BRO NPs - 4h30min
  
22
length scale characteristic for the density distribution.
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5. DISCUSSION
The formulation of a nanoparticulate carrier exploiting mucolytic agents able to cleave the
glycoprotein substructures of mucus is a suitable strategy to improve drug oral bioavailability.
Within  this  research  the  permeation  ability  of  two  NPs  systems  decorated  with  mucolytic
agents was compared. One system bearing PAP showed enhanced permeation property
compared to bare NPs in a preliminary in vivo study. The other system bearing BRO should
possess at least equal permeation ability, according to rheological tests [7], but being more
tolerated by patient, according to human in vivo tests [18]. The enzymes were conjugated via
carbodiimide  chemistry  to  PAA.  The  synthesis  procedure  leads  to  a  high  yield  and  to
comparable products in terms of enzyme content. Considering the simple procedure carried
out,  a  scale  up  seems  feasible.  The  reaction  was  performed  under  mild  condition  that
preserved the functionality of both enzymes. However, after conjugation BRO preserved its
enzymatic activity to a higher extend compared to PAP. The NPs formulation could be carried
out efficiently by ionic gelation method. The enzyme content for both enzyme-decorated NPs
was similar and the enzymatic activity maintained.
The cytotoxicity of polymers and particles was assessed by resazurin test. This assay was
choose as no need of medium removal after sample incubation is needed. In fact, during the 4
h  experiment  the  cells  can  detach  from  the  bottom  of  the  wells  due  to  the  action  of  the
proteolytic  agents  leading  to  false  results  in  case  of  medium removal.  On the  one  hand,  the
polymer  PAA-BRO resulted  to  be  more  toxic  than  PAA-PAP on  Caco-2  cells.  On the  other
hand, both types of particles exhibit low toxicity when incubated at concentrations lower than
0.2 mg/mL.
As particle size and surface charge of the two types of particles were similar, the difference in
permeation properties between PAA-PAP NPs and PAA-BRO NPs can be ascribed only to
the mucolytic activity of the coupled enzyme and not to the physic-chemical properties of the
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NPs. The permeation ability of the enzyme decorated NPs through porcine Imucus was first
assessed on a mm scale by the rotating tube technique. Exploiting this test it was possible to
assess  that  the  conjugation  with  BRO increased  the  permeation  ability  of  bare  particles  to  a
higher extent compared to PAA-PAP NPs making PAA-BRO NPs a more interesting mucus
permeating carrier. This  higher  permeation  performance  of  PAA-BRO  NPs  could  be
ascribed to the higher stability of BRO upon polymer conjugation resulting in a lower
activity loss compared to PAA-PAP NPs. As control, PAA NPs were analyzed confirming
the low permeation feature.
The diffusion of the Imucin was measured by PGSE-NMR. In concentrated biopolymer
systems  such  as  mucus,  an  analysis  of  the  diffusion  data  is  often  complex  as  the  observed
mobility which may span a wide range of value, is dependent on many factors, including but
not  limited  to  the  molecular  weight,  the  polydispersity  of  the  diffusing  species,  the
heterogeneity in gel (physical) structure and/or heterogeneity in the mucin (chemical)
structure. Therefore, the transport of NPs through such a gel will obviously be dependent on
the underlying dynamics of the gel itself (e.g. rheology), superimposed on the effects any
interactions between the NPs and the mucin or other components present in the mucus (e,g,
protein adsorption to the particle surfaces). Disentangling the relative importance of the
underlying gel dynamics and any further retardation of the particles due to specific binding, is
essential if one is to isolate the effects of cleavage of the gel, and thus, optimise the delivery
strategy.
To  this  end,  the  permeation  of  the  NPs  through  mucus  gels,  which  is  a  net  effect  of  all
interactions, may be compared with the NMR determined diffusion of the gel, which is
limited to the structure of mucin itself. Therefore, consider first the rather coarse diffusion
coefficient ratio derived from the weighted averages of the fast and slow components. When
incubated with PAA-PAP and PAA-BRO NPs there is  an increase in the rate of diffusion of
  
25
the mucin, consistent with the proteolytic cleavage of the mucin strands, leading to polymers
of lower molecular weight that will inherently possess a larger diffusion coefficient. This
observation confirms that NPs surface decoration with mucolytic enzymes leads to increased
permeation. Moreover, it appears that PAA-BRO NPs have the most significant effect on the
mucin gel diffusion compared with PAA-PAP NPs. In fact, PAA-BRO NPs action leads to a
substantially increased (x10) rate of diffusion of the slow component. These increases are
comparable to the increases observed in the permeation study, suggesting a strong correlation
between  the  two  facets  of  the  system.  However,  further  work  is  required  to  understand  the
mode of action of the enzyme decorated NPs in order to more fully contrast the relative merits
of PAP and BRO, in order to draw out stronger correlations with the permeation enhancement
observed in the in vitro assay.
Taken together, the two scattering experiments reinforce the insights gained from the
diffusion analysis. The bare particles do not lead to any large scale destruction in the structure
and thus their mobility through the gel is somewhat limited. The surface decorated particles
induce a loss of structure on a long lengthscale but with little effect on the conformation of the
constituent polymers. The simple conclusion may be drawn is that the enzymes induce a very
localized destruction in cross-linking density, leading to their greater mobility through the
mucus associated with a greater mobility of the mucus itself. What is not clear from this data
is precisely how the reduction in cross-linking density is achieved but it is known that both
enzymes possess a broad specificity. PAP exhibits a preference for hydrophobic amino acid at
position P2 especially for Phe and Tyr and for Gly, Met, Cys and Arg at position P1 and does
not accept Val at position P1' [32], whereas BRO preferentially cleaves the carbonyl terminal
site of  lysine, alanine, glycine and tyrosine [33].
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6. CONCLUSION
With the aim to design new oral DDSs able to overcome the intestinal mucus barrier PAP and
BRO  were  conjugated  to  PAA.  With  these  modified  polymers  NPs  could  be  formulated
presenting similar physic-chemical properties in term of particles size, zeta potential and
enzyme content. The ability of the NPs in permeating porcine mucus and the changes in the
mucus gel layer structure provoke by these systems were evaluated providing an inside from a
nanometer to a microns lengthscale. The results obtained from the different technique used
showed a strong correlation. In all tests BRO modified NPs exhibit the most significant effect
in altering the mucus structure and the higher performance in permeating a fresh mucus layer
compared to PAP conjugated NPs. Accordingly, the modification with BRO can further
improve the permeability of PAA NPs and, therefore, this system can be exploited as a drug
carrier able to transport the therapeutic payload through the mucus barrier and consequently
able to improve the bioavailability of orally administered drugs.
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CAPTIONS:
Table 1. Characteristics of the synthetized polymers. Results are the mean of four different
synthesis of each polymer (± standard deviation).
Table 2. Characteristics of the tested nanoparticles. Results are the mean of four different
formulations per each sample (± standard deviation).
Table 3.  Absolute and relative diffusion coefficients for Imucin in the presence of the three
nanoparticles; PAA NPs, PAA-PAP NPs and PAA-BRO NPs.
Figure 1. Schematic representation of the rotating tube technique.
Figure 2. Cytotoxicity of PAA-PAP (white bars), PAA-PAP NPs (dotted bars), PAA-BRO
(gray bars) and PAA-BRO NPs (striped bars) determined by resazurin assay after 4 h
incubation with Caco-2 cells.  Values are the means of three experiments (± standard
deviation).
Figure 3. Permeation studies of PAA NPs (black bars), PAA-PAP NPs (dotted bars) and
PAA-BRO NPs (gray bars), in porcine Imucus. Particles suspended in SIF pH 6.8 were
incubated for 4 h at 37°C. * p<0.05 vs PAA NPs, ** p<0.05 vs PAA-PAP NPs. Values are the
means of six experiments (± standard deviation).
Figure 4. Raw  PGSE-NMR  data  from  which  the  diffusion  coefficient  of  the  Imucin  and
related components were extracted.
Figure 5.  Scattering intensity I(Q) as a function of wavevector Q for Imucus and the same in
the presence of 1wt% PAA-PAP NPs and the equivalent amount of free enzyme.
Figure 6. Scattering intensity I(Q) as a function of wavevector Q for Imucus and the same in
the presence of 1wt% PAA-BRO NPs and the equivalent amount of free enzyme.
Figure 7. Polarization as a function of spin echo for Imucus and the same in the presence of
1wt% PAA-PAP NPs incubated for 0h45m and 4h30min. The arrow indicates the largest
  
30
length scale characteristic for the density distribution.
Figure 8. Polarization as a function of spin echo for Imucus and the same in the presence of
1wt% PAA-BRO NPs incubated for 0h10m and 4h30min. The arrow indicates the largest
length scale characteristic for the density distribution.
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· Nanoparticles were formulated with papain and bromelain modified poly(acrylic acid)
· Inside from a nm to a μm lengthscale of particles mucus permeation ability is given
· Particles bearing bromelain show higher permeation ability then papain particles
· Bromelain particles exhibit the most relevant effect in altering mucus structure
· Bromelain decorated particles can be exploited as oral drug delivery system
